Fitusiran Reduced Bleeding Regardless of Inhibitor Status

Fitusiran Reduced Bleeding Regardless of Inhibitor Status

314255

Fitusiran Reduced Bleeding Regardless of Inhibitor Status

Monthly treatment with the investigational medication fitusiran can reduce bleeding in people with hemophilia A and B, with or without inhibitors, according to data from two Phase 3 clinical trials. “We are encouraged by the data from these initial Phase 3 studies demonstrating fitusiran’s potential as a new therapeutic option for people with hemophilia A or B, regardless of inhibitor status,” Dietmar Berger, MD, PhD, said in a press release. Berger is head of global…

You must be logged in to read/download the full post.